Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 2
1984 1
1987 1
1992 2
1993 1
1995 1
1998 1
1999 3
2000 4
2001 2
2002 1
2003 3
2004 5
2005 4
2006 2
2007 7
2008 10
2009 5
2010 4
2011 5
2012 8
2013 3
2014 4
2015 5
2016 5
2017 4
2019 1
2020 2
2021 4
2022 5
2023 6
2024 8
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

107 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
Lauper K, Iudici M, Mongin D, Bergstra SA, Choquette D, Codreanu C, Cordtz R, De Cock D, Dreyer L, Elkayam O, Hauge EM, Huschek D, Hyrich KL, Iannone F, Inanc N, Kearsley-Fleet L, Kristianslund EK, Kvien TK, Leeb BF, Lukina G, Nordström DC, Pavelka K, Pombo-Suarez M, Rotar Z, Santos MJ, Strangfeld A, Verschueren P, Courvoisier DS, Finckh A. Lauper K, et al. Among authors: choquette d. Ann Rheum Dis. 2022 Oct;81(10):1358-1366. doi: 10.1136/annrheumdis-2022-222586. Epub 2022 Jun 15. Ann Rheum Dis. 2022. PMID: 35705376 Free PMC article.
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
Aymon R, Mongin D, Bergstra SA, Choquette D, Codreanu C, De Cock D, Dreyer L, Elkayam O, Huschek D, Hyrich KL, Iannone F, Inanc N, Kearsley-Fleet L, Koca SS, Kvien TK, Leeb BF, Lukina G, Nordström DC, Pavelka K, Pombo-Suarez M, Rodrigues A, Rotar Z, Strangfeld A, Verschueren P, Westermann R, Zavada J, Courvoisier DS, Finckh A, Lauper K. Aymon R, et al. Among authors: choquette d. Ann Rheum Dis. 2024 Mar 12;83(4):421-428. doi: 10.1136/ard-2023-224670. Ann Rheum Dis. 2024. PMID: 38071508 Free PMC article.
Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries.
Aymon R, Mongin D, Guemara R, Salis Z, Askling J, Choquette D, Codreanu C, Di Giuseppe D, Flouri I, Huschek D, Hyrich KL, Iannone F, Kvien TK, Leeb BF, Nordström D, Otero-Varela L, Pavelka K, Pombo-Suarez M, Rodrigues A, Rotar Z, Sidiropoulos P, Provan SA, Strangfeld A, Nina T, Zavada J, Kearsley-Fleet L, Courvoisier DS, Finckh A, Lauper K. Aymon R, et al. Among authors: choquette d. Arthritis Rheumatol. 2025 Sep;77(9):1194-1204. doi: 10.1002/art.43188. Epub 2025 May 21. Arthritis Rheumatol. 2025. PMID: 40230232 Free PMC article.
After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries.
Pombo-Suarez M, Sanchez-Piedra C, Gómez-Reino J, Lauper K, Mongin D, Iannone F, Pavelka K, Nordström DC, Inanc N, Codreanu C, Hyrich KL, Choquette D, Strangfeld A, Leeb BF, Rotar Z, Rodrigues A, Kristianslund EK, Kvien TK, Elkayam O, Lukina G, Bergstra SA, Finckh A, Courvoisier DS. Pombo-Suarez M, et al. Among authors: choquette d. Ann Rheum Dis. 2023 Feb;82(2):175-181. doi: 10.1136/ard-2022-222835. Epub 2022 Sep 13. Ann Rheum Dis. 2023. PMID: 36100351 Free article.
The challenge of indication extrapolation for infliximab biosimilars.
Feagan BG, Choquette D, Ghosh S, Gladman DD, Ho V, Meibohm B, Zou G, Xu Z, Shankar G, Sealey DC, Russell AS. Feagan BG, et al. Among authors: choquette d. Biologicals. 2014 Jul;42(4):177-83. doi: 10.1016/j.biologicals.2014.05.005. Epub 2014 Jun 21. Biologicals. 2014. PMID: 24962198 Free article. Review.
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies.
Lauper K, Mongin D, Bergstra SA, Choquette D, Codreanu C, Gottenberg JE, Kubo S, Hetland ML, Iannone F, Kristianslund EK, Kvien TK, Lukina G, Mariette X, Nordström DC, Pavelka K, Pombo-Suarez M, Rotar Z, Santos MJ, Tanaka Y, Turesson C, Courvoisier DS, Finckh A, Gabay C. Lauper K, et al. Among authors: choquette d. Joint Bone Spine. 2024 Mar;91(2):105671. doi: 10.1016/j.jbspin.2023.105671. Epub 2023 Nov 30. Joint Bone Spine. 2024. PMID: 38042363 Free article.
Tofacitinib Safety and Effectiveness in Canadian Patients with Rheumatoid Arthritis by Cardiovascular Risk Enrichment: Subanalysis of the CANTORAL Study.
Haraoui B, Khraishi M, Choquette D, Fortin I, Kinch CD, Galos C, Roy P, Gruben D, Vaillancourt J, Sampalis JS, Keystone EC. Haraoui B, et al. Among authors: choquette d. Rheumatol Ther. 2024 Dec;11(6):1629-1648. doi: 10.1007/s40744-024-00719-5. Epub 2024 Nov 1. Rheumatol Ther. 2024. PMID: 39485671 Free PMC article.
Pharmacologic therapy of osteoarthritis.
Pelletier JP, Choquette D, Haraoui B, Raynauld JP, Rich E, Fernandes JC, Martel-Pelletier J. Pelletier JP, et al. Among authors: choquette d. Curr Rheumatol Rep. 1999 Oct;1(1):54-8. doi: 10.1007/s11926-999-0026-0. Curr Rheumatol Rep. 1999. PMID: 11123016 Review.
107 results